News, Resources, and Events Tagged "Research Funding"
Call for Applications: Senior Sponsored Research Administrator, Harvard Law School
Job-Specific Responsibilities Reporting to the Associate Dean for Finance/CFO, the Senior Sponsored Programs Administrator engages with Harvard Law School’s research programs and faculty-sponsored research areas as a…
Compensating for research risk: permissible but not obligatory
When payment is offered for controlled human infection model (CHIM) research, ethical concerns may be heightened due to unfamiliarity with this study design as well as perceptions—and misperceptions…
Private Funding of Drug Discovery: Ethical Issues, Practical Alternatives: A Health Policy and Bioethics Consortium
Description The traditional model for drug development begins with publicly-funded science based in academic or government laboratories before private investors and for-profit pharmaceutical manufacturers become involved with their substantial expertise…
Economic vulnerability and payment for research participation
Abstract: There has been significant analysis of the ethical and regulatory issues involved with paying research participants, but less attention has been focused specifically on paying economically vulnerable individuals and…
First Opinion: Do large pharma companies provide drug development innovation?: Our analysis says no
From the article: Large pharmaceutical companies oppose legislation being considered by Congress to lower the prices of prescription drugs. Reducing their revenues, they contend, will reduce their investment in drug…
Apple’s Reach Reshapes Medical Research: The company’s tools enable researchers to track huge numbers of people. But doctors do not yet know if it will significantly improve health outcomes.
[...] The new ingredients allowing the huge scale: Apple’s iPhones, apps and money. Harvard’s new study is just one of three new large research efforts that Apple…
Celebrating the pursuit of scientific innovation: We should all be thankful to Vannevar Bush, one of the true titans of science in the 20th century.
From the article: Seventy-five years ago, President Franklin Delano Roosevelt penned a letter to his director of the Office of Scientific Research and Development, Dr. Vannevar Bush. Basking in the…
Who Owns H.I.V.-Prevention Drugs? The Taxpayers, U.S. Says: In an unexpected lawsuit, federal officials claim that Gilead Sciences willfully disregarded government patents on medicines necessary to end the AIDS epidemic.
After years of prodding by patient advocates, federal officials on Wednesday sued the drug maker Gilead Sciences, charging that it had infringed government patents on the idea of preventing H…
Book Launch: Transparency in Health and Health Care in the United States
Description In June 2019, Cambridge University Press published Transparency in Health and Health Care in the United States. This volume, edited by Holly Fernandez Lynch, I. Glenn Cohen, Carmel Shachar, and…
Grants
From the abstract: Innovation is a primary source of economic growth and is accordingly the target of substantial academic and government attention. Grants are a key tool in the government…
Drug Pricing Policies in the United States and Globally: From Development to Delivery
Couldn't join us? Check out the conversation on Twitter: @PetrieFlom #drugpricing and some of our speakers' slide presentations below! Description This one-day conference explored the current pharmaceutical pricing landscape…
New Funding Frontiers: Innovative Funding Models in Translational Research
The working group briefing book is available now for download. Description This one-day working group and conference explored the challenges in pursuing for-profit private funding for early stage translational research.…
The Petrie-Flom Center Launches the Innovative Funding Models in Translational Research Project
January 30, 2018 - The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School is launching the Innovative Funding Models in Translational Research Project to explore the bioethical,…
Bernie Sanders Tells Big Pharma: Stop Making Americans Pay Twice
[...] Other experts told IBT federal support of drug development goes well beyond just funding research. “It’s not so much the money we are actually spending through NIH.…
Private Investment vs. Public Funding in Therapeutic Development: A Health Policy and Bioethics Consortium
Panelists Bhaven Sampat, PhD, Professor of Health Policy and Management, Columbia University Mailman School of Public Health Terry McGuire, MS, MBA, Founding Partner, Polaris Partners Learn more about the Health…
Junior Research Scholar, Sports and Society Program, NYU School of Professional Studies
JR. RESEARCH SCHOLAR: NYU School of Professional Studies, Sports and Society Program We are seeking a researcher for the NYU SPS Sports and Society Program. It is an independent think…
2017 Call for Proposals: Policies for Action: Policy and Law Research to Build a Culture of Health, Robert Wood Johnson Foundation
Purpose Policies for Action: Policy and Law Research to Build a Culture of Health (P4A) was created to help build the evidence base for policies that can help…
President-Elect Trump’s Health Policy Agenda: Priorities, Strategies, and Predictions
The Petrie-Flom Center hosted a live web panel to address what health care reform might look like under President-elect Trump's administration. Expert panelists discussed the future of the Affordable…
Harnessing the U.S. Taxpayer to Fight Cancer and Make Profits
From the article: Rachel Sachs, an associate law professor at Washington University in St. Louis and expert in innovation policy, said the government had every right to seek price concessions.…
Paying Research Participants: Ethical and Regulatory Parameters
Couldn't make it to the event? Check out some of the speakers' slide presentations below! Description This symposium brought together a variety of experts to discuss key ethical and…
Big Data Neglects Populations Most in Need of Medical and Public Health Research and Interventions
Originally presented as a paper at the 2016 Petrie-Flom Center Annual Conference: Big Data, Health Law, and Bioethics. Check out the event website to watch video of this and other presentations! …
The FDA is prohibited from going germline
Petrie-Flom Faculty Director I. Glenn Cohen has co-authored a new article in Science magazine addressing recent legislation preventing the FDA from approving any research "in which a human embryo is…
Academic Fellow Rachel Sachs featured in Politico’s “Prescription Pulse”: Weekly round-up of pharma news includes Sachs on 'march-in' rights
REALITY CHECK ON 'MARCH-IN'-RIGHTS — 50 House Democrats wrote HHS and NIH last week that the government should exercise its march-in rights — handing over the patents on some high-priced…
Review of Human subjects research regulation: perspectives on the future: by I. Glenn Cohen (Faculty Director) & Holly F. Lynch (Executive Director) (eds.):
Petrie-Flom Visiting Scholar Lydia Stewart Ferreira, currently Adjunct Professor at the University of Toronto Faculty of Law and Osgoode Hall Law School, recently published a review of I. Glenn Cohen …
Legal and Ethical Issues in Healthcare Start-Ups: (followed by Petrie-Flom's 2014 Open House)
New healthcare start-ups face a range of legal and ethical challenges as they develop new products and services and solicit financial support from investors. Building on the success of the…
Do Fixed Patent Terms Distort Innovation?: Evidence from Cancer Clinical Trials
Abstract: Patents award innovators a fixed period of market exclusivity, e.g., 20 years in the United States. Yet, since in many industries firms file patents at the time of discovery (…
Responsibility and Integrity in the Pharmaceutical Industry
Video of this event is now available online: The Petrie-Flom Center hosted a lecture by Neil Flanzraich on responsible pricing strategy, access to care, clinical trial design, outsourcing, and other…
Health Law Workshop: Aaron Kesselheim
Presentation Professor Kesselheim's paper, "Do March-In Rights Protect Public Interests in Medical Products Arising from Federally-Funded Research?", is not available online. Please email Kaitlin Burroughs at kburroughs@law.harvard…
Pharma manufacturing woes dog industry
[...] While many of these problems arise from quality control failures, according to Nicholson Price from Harvard Law School’s Petrie-Flom centre for health law policy, biotechnology and bioethics, this…